{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:16:21Z","timestamp":1740122181372,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["MISP"],"award-info":[{"award-number":["MISP"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P30-ES006096"],"award-info":[{"award-number":["P30-ES006096"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s10620-017-4895-1","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T05:02:43Z","timestamp":1515733363000},"page":"645-652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV\/HIV Coinfected Patients"],"prefix":"10.1007","volume":"63","author":[{"given":"Enass A.","family":"Abdel-hameed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan D.","family":"Rouster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ceejay L.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Biesiada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Medvedovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-0019","authenticated-orcid":false,"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"4895_CR1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/QAI.0b013e3181f6d916","volume":"55","author":"KE Sherman","year":"2010","unstructured":"Sherman KE, Andersen JW, Butt AA, et al. Sustained long-term antiviral maintenance therapy in HCV\/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr. 2010;55:597\u2013605.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4895_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","volume":"55","author":"P Halfon","year":"2011","unstructured":"Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 2011;55:192\u2013206.","journal-title":"J Hepatol"},{"key":"4895_CR3","doi-asserted-by":"publisher","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","volume":"2","author":"L Rong","year":"2010","unstructured":"Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med. 2010;2:30ra32.","journal-title":"Sci Transl Med"},{"key":"4895_CR4","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756\u20131765.","journal-title":"Lancet"},{"key":"4895_CR5","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1086\/591141","volume":"198","author":"DJ Bartels","year":"2008","unstructured":"Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis. 2008;198:800\u2013807.","journal-title":"J Infect Dis"},{"key":"4895_CR6","unstructured":"Zepatier\u00ae [package insert]. Merck Sharpe & Dohme Corp.; 2016. \n                    http:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf\n                    \n                  ."},{"key":"4895_CR7","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Zepatier NDA 208261 Medical Division Director Summary Review, January, 28, 2016. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208261Orig1s000SumR.pdf\n                    \n                  ."},{"key":"4895_CR8","doi-asserted-by":"publisher","first-page":"6346","DOI":"10.3390\/v7122941","volume":"7","author":"S Fourati","year":"2015","unstructured":"Fourati S, Pawlotsky JM. Virologic tools for HCV drug resistance testing. Viruses. 2015;7:6346\u20136359.","journal-title":"Viruses"},{"key":"4895_CR9","doi-asserted-by":"publisher","first-page":"e0134395","DOI":"10.1371\/journal.pone.0134395","volume":"10","author":"J Dietz","year":"2015","unstructured":"Dietz J, Susser S, Berkowski C, et al. Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients. PLoS One. 2015;10:e0134395.","journal-title":"PLoS One"},{"key":"4895_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/QAI.0000000000001256","volume":"74","author":"EA Abdel-Hameed","year":"2017","unstructured":"Abdel-Hameed EA, Rouster SD, Zhang X, et al. Characterization of HCV NS3 protease variants in HCV\/HIV coinfected patients by ultra-deep sequence analysis: relationship with hepatic fibrosis. J Acquir Immune Defic Syndr. 2017;74:353\u2013358.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4895_CR11","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","volume":"66","author":"S Zeuzem","year":"2017","unstructured":"Zeuzem S, Mizokami M, Pianko S, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66:910\u2013918.","journal-title":"J Hepatol"},{"key":"4895_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.antiviral.2015.12.005","volume":"126","author":"A Bergfors","year":"2016","unstructured":"Bergfors A, Leenheer D, Bergqvist A, Ameur A, Lennerstrand J. Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing. Antivir Res. 2016;126:81\u201389.","journal-title":"Antivir Res"},{"key":"4895_CR13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40265-017-0753-x","volume":"77","author":"S Bagaglio","year":"2017","unstructured":"Bagaglio S, Uberti-Foppa C, Morsica G. Resistance mechanisms in hepatitis C virus: implications for direct-acting antiviral use. Drugs. 2017;77:1043\u20131055.","journal-title":"Drugs"},{"key":"4895_CR14","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jama.2015.1373","volume":"313","author":"A Osinusi","year":"2015","unstructured":"Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA.. 2015;313:1232\u20131239.","journal-title":"JAMA."},{"key":"4895_CR15","unstructured":"Hernandez D, Pant S, Zhou N, McPhee F. NS5A & NS5B minor variant analyses in HCV\/HIV patients failing treatment with DCV\/SOF. CROI, February 22\u201325, 2016, Boston, Massachusetts, Abstract Number: 575."},{"key":"4895_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijid.2016.06.020","volume":"49","author":"SG Parisi","year":"2016","unstructured":"Parisi SG, Loregian A, Andreis S, et al. Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin. Int J Infect Dis. 2016;49:151\u2013153.","journal-title":"Int J Infect Dis"},{"key":"4895_CR17","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"M Sulkowski","year":"2015","unstructured":"Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8\u00a0weeks versus 12\u00a0weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1087\u20131097.","journal-title":"Lancet"},{"key":"4895_CR18","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3851\/IMP2091","volume":"17","author":"Z Plaza","year":"2012","unstructured":"Plaza Z, Soriano V, Vispo E, et al. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. Antivir Ther. 2012;17:921\u2013926.","journal-title":"Antivir Ther"},{"key":"4895_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12328-016-0693-0","volume":"10","author":"N Hirashima","year":"2017","unstructured":"Hirashima N, Iwase H, Shimada M, et al. Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir. Clin J Gastroenterol. 2017;10:41\u201346.","journal-title":"Clin J Gastroenterol"},{"key":"4895_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa1501315","volume":"373","author":"S Naggie","year":"2015","unstructured":"Naggie S, Cooper C, Saag M, et al. ION-4 investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705\u2013713.","journal-title":"N Engl J Med"},{"key":"4895_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486\u2013504. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2015.09.011\n                    \n                  .","journal-title":"J Hepatol"},{"key":"4895_CR22","doi-asserted-by":"publisher","first-page":"20310","DOI":"10.1038\/srep20310","volume":"6","author":"ZW Chen","year":"2016","unstructured":"Chen ZW, Li H, Ren H, Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep. 2016;6:20310.","journal-title":"Sci Rep"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-017-4895-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4895-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4895-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T14:39:44Z","timestamp":1589726384000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-017-4895-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["4895"],"URL":"https:\/\/doi.org\/10.1007\/s10620-017-4895-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2018,1,12]]},"assertion":[{"value":"8 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K.E.S. has received research support (to institution) from AbbVie, BMS, Gilead, Merck, MedImmune, Innovio. K.E.S. has served as a consultant to Gilead, Merck, MedImmune, and Abbott Labs. The authors E.A.A., S.D.R., C.L.B., X.Z., J.C., J.B., and M.M. have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}